+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID06966232

Phase 3 Study Comparing Preventive Versus Early Use of Entecavir in Patients With Gastrointestinal Cancer and Inactive Hepatitis B During Chemotherapy or Immunotherapy

Led by Sun Yat-sen University · Updated on 2025-05-11

136

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of two different strategies for using the antiviral drug entecavir in patients with gastrointestinal cancers who are also inactive carriers of hepatitis B virus. This phase 3, open, multicenter, randomized controlled trial aims to compare prophylactic use versus preemptive use of entecavir during chemotherapy or immunotherapy and subsequent follow-up periods. The study addresses an important question since it is currently unclear whether inactive hepatitis B carriers with gastrointestinal cancer should receive entecavir preventively or only if viral reactivation occurs during anti-tumor treatment. Participants are assigned to one of two groups. The experimental group receives entecavir at 0.5 mg orally every day starting from the beginning of chemotherapy or immunotherapy and continuing until 6 months after treatment ends. The comparator group receives entecavir at the same dose only if hepatitis B virus DNA becomes detectable during treatment, continuing for 6 months after therapy completion. This design includes two cohorts receiving chemotherapy or immunotherapy, enabling comparison of antiviral strategies alongside different anti-tumor therapies. During the study, patients undergo regular monitoring for hepatitis B virus reactivation and liver function over an average follow-up of one year. Researchers assess the incidence of viral reactivation as the primary outcome, along with secondary outcomes such as hepatitis occurrence, interruption of anti-tumor therapy due to hepatitis, severe HBV-related hepatitis, acute liver failure, and related deaths. Patients are closely followed for safety and treatment adherence throughout chemotherapy or immunotherapy and the 6-month post-treatment period, with laboratory tests and clinical evaluations conducted at scheduled intervals.

CONDITIONS

Brief Title

Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers

Research Team

X

Xu Rui-hua, M.D. Ph.D

W

Wang Feng, M.D. Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here